Regulatory approval
Published by the Food and Drug Administration.
The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.
This is written in the approval document as:
FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
Citation
AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive | Invasive Breast Carcinoma | Fulvestrant | |
| Sensitivity (+) | PR positive | Invasive Breast Carcinoma | Fulvestrant | |
| Sensitivity (+) | ER positive, PR positive | Invasive Breast Carcinoma | Fulvestrant |